8-K: Propanc Biopharma Secures $61,000 in Convertible Debt Financing

Propanc Biopharma has entered into two securities purchase agreements to secure a total of $61,000 in convertible debt financing for working capital.

Summary

• Propanc Biopharma has secured $61,000 in funding through two separate convertible note agreements.
• The first agreement, dated December 13, 2024, involves a $22,000 note with an 8% interest rate, purchased for $20,000 after a $2,000 original issue discount.
• This note matures on June 15, 2025, and interest payments can be made in common stock.
• The second agreement, dated December 4, 2024, is for a $49,200 note, purchased for $41,000 after an $8,200 original issue discount.
• This note has a one-time 15% interest charge applied on the issue date, and the principal and interest are to be paid in five installments between June 15, 2025 and October 15, 2025.
• Both notes are convertible into common stock, with the conversion price for the first note initially at $0.0003 per share, potentially decreasing to $0.0001 if the stock trades below $0.0003 for five consecutive days.
• The second note's conversion price is 65% of the lowest trading price in the ten days prior to conversion.
• The company intends to use the net proceeds from these notes for general working capital purposes.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high-risk nature of the financing, the potential for significant dilution, and the default provisions. While the company has secured funding, the terms are not favorable for existing shareholders.

Positives

• The company has successfully raised $61,000 in capital through convertible notes.
• The notes provide flexibility with conversion options into common stock.
• The second note has no prepayment penalty, offering the company flexibility.
• The company has the option to prepay the first note within 180 days, albeit with a premium.

Negatives

• The notes include default provisions that could trigger immediate repayment.
• The conversion of the notes could lead to significant dilution of existing shareholders.
• The first note has a prepayment premium if prepaid within 180 days.
• The second note has a one-time 15% interest charge applied on the issue date.

Risks

• Failure to meet payment obligations or maintain stock listing could trigger default on the notes.
• The conversion of the notes could significantly dilute existing shareholders.
• The company's ability to repay the notes depends on its future financial performance.
• The company's stock price could be negatively impacted by the potential dilution from the conversion of the notes.

Future Outlook

The company intends to use the net proceeds from these notes for general working capital purposes. The company is required to maintain a reserve of shares for conversion of the notes.

Industry Context

The use of convertible notes is a common method for small and micro-cap companies to raise capital, particularly when access to traditional financing is limited. The terms of these notes, including the conversion prices and default provisions, are typical for this type of financing.

Comparison to Industry Standards

• The conversion price of $0.0003 per share for the first note, potentially decreasing to $0.0001, is very low, reflecting the high-risk nature of the investment and the company's current stock price.
• The 35% discount on the conversion price for the second note is also typical for this type of financing, providing an incentive for the investor.
• The default provisions, including failure to maintain listing and breaches of covenants, are standard in convertible note agreements.
• The prepayment premiums on the first note are also common, designed to compensate the investor for early repayment.
• The interest rates of 8% and 15% are within the range of what is expected for high-risk convertible debt.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of the notes.
• Creditors are now exposed to the company's financial performance.
• Employees may be impacted by the company's financial stability.
• Customers and suppliers may be affected by the company's ability to operate.

Next Steps

• The company needs to use the funds for working capital.
• The company needs to manage its stock price to avoid triggering the lower conversion price on the first note.
• The company needs to ensure compliance with all covenants to avoid default.
• The company needs to monitor the share reserve to ensure it is sufficient for potential conversions.

Key Dates

Keywords

convertible note, financing, debt, common stock, conversion, working capital, securities purchase agreement, default, interest rate, prepayment